Skip to main content
. Author manuscript; available in PMC: 2011 Jun 17.
Published in final edited form as: Oncogene. 2010 Apr 26;29(24):3453–3464. doi: 10.1038/onc.2010.127

Figure 2.

Figure 2

Simplified model of PARK2 dysfunction in cancer and familial PD. In PD, mutational inactivation of PARK2 is sufficient to raise cyclin E levels, which helps bring about neurotoxicity. In cancer cells, PARK2 mutations occur in conjunction with other oncogenic alterations, resulting in increased tumor cell growth.